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Abstract
Glucose transport in mammalian skeletal muscle is stimulated by insulin, hypoxia and tyrosine protein phosphatase
inhibitors such as vanadate. However, it is unknown whether the vanadate signaling mechanism shares a common or
separate pathway with insulin or hypoxia. Therefore, experiments were conducted on incubated human muscle strips to
 .compare the effects of vanadate with insulin and hypoxia stimulated 2-deoxyglucose transport 2-DOG . We also used the
 .phosphatidylinositol 3-kinase PI 3-kinase inhibitor wortmannin to examine whether PI 3-kinase is a common step by
which each stimulate glucose transport. Results demonstrate that whereas the effects of vanadate and hypoxia were additive
with insulin stimulated glucose transport, the effect of vanadate plus hypoxia was not. In addition, wortmannin significantly
 .P-0.05 reduced insulin but not vanadate or hypoxia stimulated 2-DOG transport. Moreover, PI 3-kinase activity was
 .significantly elevated P-0.05 in the presence of insulin but not vanadate. In conclusion, these data suggest that vanadate
and hypoxia stimulate glucose transport via a similar signaling pathway which is distinct from insulin and that the vanadate
signaling pathway is not mediated by PI3-kinase in human skeletal muscle. q 1997 Elsevier Science B.V.
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1. Introduction
Glucose transport in skeletal muscle can be stimu-
lated by multiple mechanisms, of which the insulin
stimulated pathway is best understood. Although the
complete pathway is undefined, the proximal steps
Abbreviations: BMI, body mass index; 2-DOG, 2-deoxyglu-
 w 3  .x .cose 2- 1,2- H N -deoxy-D-glucose ; KHB, Krebs–Henseleit
buffer; PI 3-kinase, phosphatidylinositol 3-kinase; Vanadate
 .Van , sodium ortho-vanadate
) Corresponding author. Tel.: q1-919-8162675; fax: q1-919-
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w xhave been described 1 . Insulin binding to the a-sub-
unit of it’s receptor results in autophosphorylation of
tyrosine residues in the receptor b-subunit and activa-
tion of a tyrosine kinase which immediately initiates
a cascade of signaling events. The initial step in the
cascade is the tyrosine phosphorylation of the insulin
 .receptor substrate 1 IRS-1 , with several potential
phosphorylation sites residing in peptide sequences
that are known to associate with proteins containing
 . w xSH2 Src homology 2 domains 2 . Included is the
85 kDa regulatory subunit of phosphatidylinositiol
 .3-kinase PI3-kinase , leading to activation of the
w xcatalytic subunit of the enzyme 3,4 . PI 3-kinase
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activation is believed to be involved in propagating
many of the intracellular signaling events responsible
for the biological actions of insulin, including Glut-4
w xtranslocation to the plasma membrane 5–7 .
w xIn addition to insulin, studies from our 8 and
w xother laboratories 9 have demonstrated that the tyro-
sine phosphatase inhibitor vanadate can stimulate
glucose transport in skeletal muscle, the results being
variable depending on the muscle source human or
. w xrat and fiber type 8,10 .
w xIn humans, Carey et al. 8 have shown that vana-
 .date stimulates 2-deoxyglucose 2-DOG transport to
a greater extent than insulin, suggesting that vanadate
may operate via a separate or additional pathway
from insulin. However, in the rat, the simultaneous
effect of insulin and vanadate has been shown to not
w xbe additive 10 suggesting that the pathways are
similar. Hypoxia has also been shown to stimulate
w xglucose transport, both in rat 11,12 and human
w x w xskeletal muscle 13 . Azevedo et al. 13 demon-
strated that hypoxia stimulation of 2-DOG, although
similar in magnitude, is additive with insulin stimula-
tion of transport suggesting that hypoxia stimulates
glucose transport in skeletal muscle by a pathway
separate or distal from insulin. Studies comparing the
simultaneous effects of vanadate and hypoxia on
hexose transport in human skeletal muscle are lack-
ing. In the rat, however, the effects of hypoxia on
muscle glucose transport has been shown to be addi-
w x w xtive with insulin 14 and with vanadate 10 .
At present, details regarding the similarities andror
 .differences in the mechanism s by which vanadate
versus insulin or hypoxia stimulate glucose transport
in skeletal muscle are poorly understood. For exam-
ple, although vanadate has been described as being
insulimetric because it had been shown to activate the
intrinsic tyrosine kinase activity of highly purified
w xinsulin receptor in vitro 15 it has since been deter-
w xmined in intact cells 16 and in several in vivo
w xstudies 17–19 that vanadate action on glucose trans-
 .port involve s a step distal to the insulin receptor. In
this regard, an essential role for PI 3-kinase in the
propagation of vanadate stimulated glucose transport
signaling has not been established.
Therefore, the purpose of this experiment was to
extend our previous findings by comparing the ef-
fects of insulin, hypoxia and vanadate on glucose
transport in the same muscle sample and to investi-
gate whether PI 3-kinase activity is necessary for




w 3  .x w 14 x2- 1,2- H N -deoxy-D-glucose, U- C -D-sorbitol
w 32 xand g- P ATP were obtained from Dupont-NEN
 .Boston, MA . Anti-phosphotyrosine antibody conju-
gated to sepharose beads was from Sigma Chemicals
 .St. Louis, MO . L-a-phosphatidylinositol was ob-
 .tained from Avanti Polar-Lipids Alabaster, AL .
Sodium ortho-vanadate was purchased from Fisher
 .Scientific Pittsburg, PA . Wortmannin was obtained
 .from Sigma Chemicals St. Louis, MO .
2.2. Human subjects
  .Eighteen lean patients body mass index BMI s
.23.3"0.6 with normal glucose tolerance and who
underwent elective surgery primarily hysterec-
.tomies served as subjects. The experimental protocol
for obtaining the muscle biopsies was approved by
the East Carolina University Policy and Review
Committee on Human Research, and informed con-
sent was obtained from all patients.
Blood samples for glucose and insulin analysis
were taken intraoperatively. Samples were processed
within 30 min, frozen at y208C and assayed glucose
oxidase method, IM , Abbott Laboratories, AbbottX
.Park, IL within several days of collection.
Surgery was performed on the patients after an
overnight fast. General anesthesia was initiated with a
short-acting barbiturate and maintained with a fen-
tanyl and nitrous oxide-oxygen mixture. A 3=2=
 .0.5 cm muscle biopsy ;3 g was obtained from the
rectus abdominus muscle after entry into the abdomi-
nal cavity. The muscle sample was placed in an
airtight container with oxygenated Krebs–Henseleit
 .buffer KHB for transport to the laboratory.
2.3. In ˝itro glucose transport
The details for measurement of glucose transport
into human muscle in our laboratory has been de-
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w xscribed elsewhere 20 . In this study, incubation ex-
periments were conducted under the following condi-
 .tions 1 basal, insulin, hypoxia, hypoxia plus insulin,
vanadate, vanadate plus insulin and vanadate plus
 .hypoxia and 2 basal, insulin, insulin plus wortman-
nin, vanadate, vanadate plus wortmannin, hypoxia,
and hypoxia plus wortmannin. In each experiment,
 .muscle strips ;25 mg were clamped in Lucite
 .clips to maintain resting length and placed into
 .separate wells containing Krebs–Heinseleit KHB
buffer plus 1% bovine serum albumin, 1.0 mmolrl
. pyruvate at 298C under normoxic 95% O r5%2
 .CO or hypoxic 95% N r5% CO conditions with2. 2 2
 .or without wortmannin 1 mM as indicated above.
 .Muscle strips were preincubated lasting 60 min
 y7 .with either insulin 10 M; lasting 10 min or
 .vanadate 30 mM, pH 8.0; lasting 30 min at concen-
trations previously shown to maximally stimulate
w xglucose transport 8,13 . Following preincubation, all
strips were transferred to incubation wells for 60
.min under identical conditions except that the media
 .contained 5.0 mM 2-deoxyglucose 2-DOG , 20 mM
w 3  .xsorbitol, 2 mCi 2- 1,2- H N -DOG to quantify glu-
w 14 xcose transport and 0.1 mCi U- C -D-sorbitol to
quantify extracellular space. Afterwards, the muscle
strips were washed, blotted, weighed and solubilized
in 0.5 ml of 0.32 molrl hexaecyltrimethyl ammo-
nium bromide and 0.29 molrl potassium hydroxide
in a 1:1 mixture of MeOH and H 0. Solubilized2
muscle strips and incubation media were counted for
radioactivity in a Beckman LS 5000 TD liquid scin-
tillation counter preset to count 14C and 3H channels
simultaneously. Data are expressed as 2-DOG trans-
port in nmolrgPmin. For measurement of PI 3-kinase
 .activity, muscle samples were incubated as above
under basal, insulin, vanadate, or vanadate plus in-
sulin conditions and then the muscle strips were
immediately frozen with metal tongs cooled in liquid
nitrogen and stored at y708C until assayed for PI3-
kinase activity.
2.4. Phosphatidylinositol 3-kinase acti˝ity
PI 3-kinase is assayed in our laboratory according
w xto a modified protocol of Chen et al. 3 . Skeletal
 .  .muscle 100–200 mg was homogenized 1r10 wrv
win cold homogenization buffer 50 mM N-2-2-hy-
droxyethyl-piperazine-N X-2-ethanesulphonic acid
 .HEPES, pH 7.4 , 150 mM NaCl, 2 mM EDTA, 10
mM Na P O , 2 mM Na VO , 1 mM MgCl , 1 mM4 2 7 3 3 2
CaCl , 10 mM NaF, 2 mM PMSF, 5 mgrml leu-2
xpeptin and 10% glycerol for 30 s on ice, solubilized
 .for 60 min Nonidet P-40, 1% vol and centrifuged
 .207,000=g, 1 h . An aliquot of the supernatant was
assayed for protein BCA method, Pierce, Rockford,
.IL . The homogenate supernatant was incubated
overnight with anti-phosphotyrosine antibody mono-
.clonal conjugated to sepharose beads at 48C. The
sepharose was then gently pelleted 10 s at 14,000
.rpm and washed 3 times with 1% Nonidet P-40 in
 .phosphate buffered saline pH 7.4 , 3 times with 0.5
 .M LiCl and 100 mM Tris pH 7.6 , and 2 times with
 .10 mM Tris pH 7.6 , 100 mM NaCl and 1 mM
EDTA. The samples were aspirated and 50 ml of
 .fresh wash buffer a3 was then added to the pro-
tein–sepharose complex. The reaction mixture con-
sisted of washed Sepharose beads, 40 mM ATP final
w 32 xconcentration with 20 mCi g- P ATP, 10.6 mM
MgCl and 10 ml of L-a-phosphatidylinositol 22
.  .mgrml sonicated in 10 mM Tris pH 7.4 and 1 mM
EGTA. After 10 min, the reaction was stopped with
20 ml of 8 N HCL and labeled lipids were extracted
 .with 200 ml of methanol–chloroform 1:1 vrv . The
extract was vortexed and briefly centrifuged 10 s at
.14,000 rpm . The organic phase was then separated
by thin layer chromatography in a mobile phase of
chloroform–methanol–ammonium hydroxide–water
 .60:47:11.3:2 vrvrvrv , developed and the reaction
 .products developed overnight were visualized on a
 wphosphoimager Phosphoimager 452E; Molecular
.Dynamics, Sunnyvale, CA . Band intensity was quan-
w tified using Imagequant software Molecular Dy-
.namics, Sunnyvale, CA . The results were normal-
ized to the protein content of the homogenate.
2.5. Statistical analysis
All data are means"SE. The vanadaterhypoxia
plus insulin 2-DOG transport and PI3-kinase activity
data were statistically analyzed by a one way re-
peated measures ANOVA and the Duncan new multi-
ple range test was used to locate the differences
between treatments. Planned comparisons established
a priori for the vanadaterhypoxia plus wortmannin
2-DOG transport data were analyzed with a Student’s
paired t-test. Significance was set at P-0.05.
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3. Results
The clinical characteristics of the patients were as
 . follows: age 38.2 " 2.7 yr , BMI 23.3 " 0.6
2.  .kgrm , serum glucose 5.1"0.2 mmolrl , serum
 .insulin 21.4"3.7 pmolrl .
As shown in Fig. 1, maximal stimulation of 2-DOG
transport by vanadate was achieved at a 30 mM
concentration, with no greater increase at higher con-
centrations. The maximal effect of vanadate on glu-
cose transport rate was approximately 5.5-fold above
basal values.
 .As expected, insulin significantly P-0.001 in-
creased glucose transport over basal maximal insulin
.response 2.4-fold; mean of experiments indicating
that skeletal muscle from these patients was respon-
 .sive to insulin Figs. 2 and 3 . This conclusion is
supported by the observed normal levels for plasma
glucose and insulin.
The results for the vanadate and hypoxia stimula-
tion of 2-DOG transport are depicted in Fig. 2.
Repeated measures ANOVA indicated a significant
 .overall effect of treatments P-0.001 . Post hoc
analysis revealed that both vanadate and hypoxia
 .significantly P-0.05 elevated glucose transport
over basal. However, the observed effect for vanadate
 .versus basal was approximately 2-fold greater than
for hypoxia. In addition, when compared to either
 .Fig. 1. Stimulation of 2-deoxyglucose 2-DOG transport in
human rectus abdominus muscle by different concentrations of
 .vanadate each point is mean"SE for three experiments .
Fig. 2. Effect of insulin, vanadate and hypoxia on glucose
transport in human skeletal muscle. Basal, insulin, vanadate"
insulin and hypoxia"insulin stimulation of 2-DOG transport was
 .evaluated in human skeletal muscle from lean patients: a signif-
 .  .icantly different P -0.05 from basal; b significantly different
from insulin-stimulated. Data are means"SE; Ns6 observa-
tions.
hypoxia or insulin stimulation of 2-DOG transport,
 .vanadate stimulation was significantly P-0.05
greater. Interestingly, whereas the effect of either
 .Fig. 3. Effect of wortmannin 1 mM on insulin, vanadate and
hypoxia stimulated glucose transport in human skeletal muscle.
Basal and insulin"wortmannin, vanadate"wortmannin and hy-
poxia"wortmannin 2-DOG transport was evaluated in human
 .skeletal muscle from lean patients: a treatment versus treatment
 .plus wortmannin significantly different P F0.05 . Data are
means"SE; Ns5 observations.
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Fig. 4. Effects of insulin and vanadate on phosphatidylinositiol
 .PI 3-kinase in human skeletal muscle. Equal amounts of solubi-
lized protein were immunoprecipitated with a-phosphotyrosine
 .antibody polyclonal and kinase reaction was carried out in the
w 32 xpresence of PI and g- P ATP with lipid products separated by
thin-layer chromatography. Spots that comigrated with PI-4-phos-
 .phate standard PIP were quantified by densitometry. Data are
means"SE; Ns7 observations. ) P -0.05 versus basal.
vanadate or hypoxia was shown to be additive with
insulin, vanadate plus hypoxia stimulation of 2-DOG
transport was not additive. This suggests that the
vanadate stimulated pathway for glucose transport is
distinct from insulin but similar to hypoxia.
The effect of the PI 3-kinase inhibitor wortmannin
 .1 mM on insulin, vanadate and hypoxia stimulation
of 2-DOG transport is shown in Fig. 3. In the pres-
ence of wortmannin, the maximally effective insulin
stimulation of glucose transport was reduced to levels
that were not significantly different from basal. Ac-
cordingly, the glucose transport rate under the insulin
plus wortmannin treatment was significantly reduced
 .Ps0.05 compared to the insulin condition. In
contrast, neither the vanadate nor hypoxia stimulated
2-DOG transport was affected by wortmannin. These
data are indicative of PI 3-kinase’s involvement in
insulin but not vanadate or hypoxia stimulated glu-
cose transport.
Insulin stimulated PI 3-kinase activity 3.0"0.7-
 .fold over basal P-0.05 whereas PI 3-kinase activ-
 .ity was not significantly elevated 1.8"0.3-fold
 .over basal by vanadate Fig. 4 . Furthermore, the
difference in PI 3-kinase activity between vanadate
 .plus insulin 2.6"0.4-fold versus insulin were also
non-significant. Thus, as suggested by the wortman-
nin data, PI 3-kinase does not appear to be a neces-
sary component for vanadate stimulation of glucose
transport in human skeletal muscle.
4. Discussion
Glucose transport in skeletal muscle is stimulated
w x w xby insulin 1 hypoxia 13,14 or muscle contractions
w x9,11 and the tyrosine protein phosphatase inhibitor
w xvanadate 8,16,21 . Although the complete pathway
by which insulin stimulates glucose transport is un-
known, activation of PI 3-kinase is believed to be an
important component of the insulin signaling cascade
w xin skeletal muscle 1,22,23 . In contrast, studies in the
rat generally accept that hypoxia stimulates glucose
transport by a PI 3-kinase independent mechanism
w x11,12 . At present however, it is unknown whether
PI 3-kinase is involved in the signaling pathway by
which vanadate stimulates glucose transport. There-
fore, the purpose of this study was to determine
whether PI 3-kinase activity is necessary for vanadate
stimulated glucose transport in human skeletal mus-
cle. Furthermore, we wished to determine whether
vanadate and hypoxia stimulate glucose transport via
a common or separate pathway. The major findings
 .of this study are 1 in human skeletal muscle, neither
vanadate nor hypoxia stimulation of glucose transport
 .appear to act through PI 3-kinase and 2 vanadate
and hypoxia appear to stimulate glucose transport via
a common pathway.
Vanadate stimulated glucose transport 2.3-fold
 .greater than insulin Fig. 2 . This finding suggests
that vanadate can enhance glucose transport in mus-
cle from insulin sensitive individuals to a greater
extent than insulin. One possible explanation for this
finding could be that vanadate acts to inhibit the
phosphatases that regulate the insulin signaling path-
way. Alternatively, there may be a capacity for glu-
cose transport available that is not called upon by
insulin, but which is activated by vanadate. For ex-
ample, vanadate may stimulate both the insulin sig-
naling pathway and the hypoxiarcontraction stimu-
lated pathway, which has been suggested as being
separate from the insulin signaling pathway
w x14,24,25 . Thus, by effecting two signaling path-
ways, vanadate could elicit glucose transport to a
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w xgreater extent than insulin. In support, Carey et al. 8
observed that vanadate plus insulin increased glucose
transport greater than insulin alone in obese, insulin
insensitive individuals, indicating an intact effector
system that has been stimulated by vanadate either at
a point distal to the signaling defect associated with
insulin resistance, or by a separate mechanism.
In contrast to vanadate, hypoxia stimulation of
glucose transport was similar to insulin. Previous
w xresults obtained in human 13 and rat skeletal muscle
w x11,12 support this finding. In the present study, the
effect of insulin plus hypoxia on glucose transport
was additive. This suggests that like vanadate, hy-
poxia activates glucose transport by a separate mech-
anism. In contrast, the maximal effect of hypoxia
plus vanadate on hexose transport was not additive.
This is the first reported evidence to suggest that
these two stimuli may share a common mechanism in
stimulating glucose transport in human skeletal mus-
cle. These results however, are in opposition to the
w xfindings of Henriksen et al. 10 . These investigators
showed a lack of additivity of vanadate with insulin,
but additivity with hypoxia. The lack of agreement
 .between Henriksen et al. 1991 and the present study
may be due to species differences as the former
findings were observed in the rat.
Indirect evidence suggests that like contractions,
the initial signal in the hypoxia pathway is an in-
w xcrease in cytosolic calcium 14 . Whether a similar
mechanism is responsible for the vanadate induced
increase in glucose transport in skeletal muscle is yet
to be determined. However, the observation that
vanadate and hypoxia stimulated glucose transport
were not additive in the present study suggests that
the vanadate mechanism may also involve changes in
cytoplasmic calcium. Future research into the possi-
ble role of changes in cytoplasmic calcium levels to
account for the effects of vanadate on muscle glucose
transport represents a logical continuation of this
study.
The present results are in contrast to previous
speculation that vanadate is insulin-mimetric. The
earlier conclusion was based on the observation that
vanadate had been shown to activate the intrinsic
tyrosine kinase activity of highly purified insulin
w xreceptor in vitro 15 . However, more recent studies
have demonstrated that little or no increase in tyro-
w xsine phosphorylation occurs in intact cells 16 treated
with vanadate and the stimulatory effect was pre-
served in adipocytes depleted of insulin receptors
w x26 . In addition, in vivo studies have documented
w xthat vanadate administration to normal 17 , insulin
w xdeficient 18 and hyperinsulinemic-insulin resistant
w xanimals 19 does not induce any detectable activa-
tion of insulin receptor tyrosine kinase under condi-
tions where glucose metabolism was stimulated.
The additivity of vanadate or hypoxia with insulin
on the stimulation of glucose transport does not
define the specific level at which the pathways may
w xdiffer 27 . Therefore, we used the PI 3-kinase in-
hibitor wortmannin to investigate whether PI 3-kinase
is involved in vanadate or hypoxia stimulated glucose
transport. Wortmannin eliminated insulin stimulation
of glucose transport, but had no effect on either
hypoxia or vanadate stimulated 2-DOG transport Fig.
.3 . Furthermore, vanadate failed to significantly ele-
vate PI 3-kinase activity, whereas the expected result
of a significant elevation in PI 3-kinase activity with
 .insulin was observed Fig. 4 . Moreover, when in-
sulin and vanadate were incubated in combination,
the effect was almost identical to insulin alone, indi-
cating that insulin but not vanadate stimulates PI
3-kinase activity. Collectively, these data provide
strong support for the hypothesis that both vanadate
and hypoxia stimulate glucose transport by a PI
3-kinase independent mechanism.
The finding that activation of glucose transport by
insulin and hypoxia are inhibited by polymyxin B
w x w x10 and sphingosine 28 indicates that the two path-
ways may posses one or more steps in common.
Moreover, the finding that wortmannin inhibited in-
sulin but not vanadate or hypoxia stimulated glucose
transport indicates that any common elements in their
signaling pathways are downstream of PI 3-kinase.
Interestingly, the results from this study emphasize
a redundancy in the muscle cell’s ability to recruit
 .glucose transporters Glut-4 to the plasma mem-
brane. Consistent with a ‘redundancy concept’ mus-
cle contractions also increase glucose transport in
w xskeletal muscle 9,11,22 . Like hypoxia, the maximal
effects of insulin plus contractions are additive sug-
gesting that both pathways are distinct from insulin
w x24,25 . Although vanadate stimulation of glucose
transport is consistent with a redundant pathway con-
cept, it can not be determined from the present data
whether these three stimuli converge. However, the
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presence of a multiple signaling pathway architecture
to transport glucose into skeletal muscle underscores
the importance of maintaining normal intrarextra-
cellular glucose concentrations.
In conclusion, findings from the present study
suggest that neither vanadate nor hypoxia increase
glucose transport by acting through PI 3-kinase. With
respect to vanadate, further support for this conclu-
sion is provided by the inability of vanadate to
elevate PI 3-kinase activity. Vanadate and hypoxia
appear to stimulate glucose transport by a similar
 .mechanism in human skeletal muscle which is sepa-
rate from the insulin signaling pathway. However, a
point of convergence for the vanadate and hypoxia
 .  .or contractions signaling pathway s with the in-
sulin signaling cascade for stimulation of glucose
transport in skeletal muscle can not be determined
from these data and represents a focal point for future
research.
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